399 related articles for article (PubMed ID: 20607239)
1. Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumors.
Dees EC; Infante JR; Cohen RB; O'Neil BH; Jones S; von Mehren M; Danaee H; Lee Y; Ecsedy J; Manfredi M; Galvin K; Stringer B; Liu H; Eton O; Fingert H; Burris H
Cancer Chemother Pharmacol; 2011 Apr; 67(4):945-54. PubMed ID: 20607239
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics.
Macarulla T; Cervantes A; Elez E; Rodríguez-Braun E; Baselga J; Roselló S; Sala G; Blasco I; Danaee H; Lee Y; Ecsedy J; Shinde V; Chakravarty A; Bowman D; Liu H; Eton O; Fingert H; Tabernero J
Mol Cancer Ther; 2010 Oct; 9(10):2844-52. PubMed ID: 20724522
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.
Schöffski P; Aftimos P; Dumez H; Deleporte A; De Block K; Costermans J; Billiet M; Meeus MA; Lee C; Schnell D; Goeldner RG; Awada A
Cancer Chemother Pharmacol; 2016 Jan; 77(1):99-108. PubMed ID: 26650227
[TBL] [Abstract][Full Text] [Related]
5. Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.
Chakravarty A; Shinde V; Tabernero J; Cervantes A; Cohen RB; Dees EC; Burris H; Infante JR; Macarulla T; Elez E; Andreu J; Rodriguez-Braun E; Rosello S; von Mehren M; Meropol NJ; Langer CJ; ONeil B; Bowman D; Zhang M; Danaee H; Faron-Yowe L; Gray G; Liu H; Pappas J; Silverman L; Simpson C; Stringer B; Tirrell S; Veiby OP; Venkatakrishnan K; Galvin K; Manfredi M; Ecsedy JA
Cancer Res; 2011 Feb; 71(3):675-85. PubMed ID: 21148750
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.
Lin CC; Su WC; Yen CJ; Hsu CH; Su WP; Yeh KH; Lu YS; Cheng AL; Huang DC; Fritsch H; Voss F; Taube T; Yang JC
Br J Cancer; 2014 May; 110(10):2434-40. PubMed ID: 24755882
[TBL] [Abstract][Full Text] [Related]
7. Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours.
Schöffski P; Jones SF; Dumez H; Infante JR; Van Mieghem E; Fowst C; Gerletti P; Xu H; Jakubczak JL; English PA; Pierce KJ; Burris HA
Eur J Cancer; 2011 Oct; 47(15):2256-64. PubMed ID: 21852114
[TBL] [Abstract][Full Text] [Related]
8. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
Cervantes A; Elez E; Roda D; Ecsedy J; Macarulla T; Venkatakrishnan K; Roselló S; Andreu J; Jung J; Sanchis-Garcia JM; Piera A; Blasco I; Maños L; Pérez-Fidalgo JA; Fingert H; Baselga J; Tabernero J
Clin Cancer Res; 2012 Sep; 18(17):4764-74. PubMed ID: 22753585
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors.
Dittrich C; Fridrik MA; Koenigsberg R; Lee C; Goeldner RG; Hilbert J; Greil R
Invest New Drugs; 2015 Apr; 33(2):409-22. PubMed ID: 25529193
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.
Dees EC; Cohen RB; von Mehren M; Stinchcombe TE; Liu H; Venkatakrishnan K; Manfredi M; Fingert H; Burris HA; Infante JR
Clin Cancer Res; 2012 Sep; 18(17):4775-84. PubMed ID: 22767670
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
[TBL] [Abstract][Full Text] [Related]
12. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
Hofheinz RD; Al-Batran SE; Hochhaus A; Jäger E; Reichardt VL; Fritsch H; Trommeshauser D; Munzert G
Clin Cancer Res; 2010 Sep; 16(18):4666-74. PubMed ID: 20682708
[TBL] [Abstract][Full Text] [Related]
13. A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors.
Mita M; Gordon M; Rejeb N; Gianella-Borradori A; Jego V; Mita A; Sarantopoulos J; Sankhala K; Mendelson D
Target Oncol; 2014 Sep; 9(3):215-24. PubMed ID: 23832397
[TBL] [Abstract][Full Text] [Related]
14. A phase 1, first-in-human study of AMG 900, an orally administered pan-Aurora kinase inhibitor, in adult patients with advanced solid tumors.
Carducci M; Shaheen M; Markman B; Hurvitz S; Mahadevan D; Kotasek D; Goodman OB; Rasmussen E; Chow V; Juan G; Friberg GR; Gamelin E; Vogl FD; Desai J
Invest New Drugs; 2018 Dec; 36(6):1060-1071. PubMed ID: 29980894
[TBL] [Abstract][Full Text] [Related]
15. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.
Manfredi MG; Ecsedy JA; Meetze KA; Balani SK; Burenkova O; Chen W; Galvin KM; Hoar KM; Huck JJ; LeRoy PJ; Ray ET; Sells TB; Stringer B; Stroud SG; Vos TJ; Weatherhead GS; Wysong DR; Zhang M; Bolen JB; Claiborne CF
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4106-11. PubMed ID: 17360485
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.
Boss DS; Witteveen PO; van der Sar J; Lolkema MP; Voest EE; Stockman PK; Ataman O; Wilson D; Das S; Schellens JH
Ann Oncol; 2011 Feb; 22(2):431-7. PubMed ID: 20924078
[TBL] [Abstract][Full Text] [Related]
18. A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors.
Sarker D; Molife R; Evans TR; Hardie M; Marriott C; Butzberger-Zimmerli P; Morrison R; Fox JA; Heise C; Louie S; Aziz N; Garzon F; Michelson G; Judson IR; Jadayel D; Braendle E; de Bono JS
Clin Cancer Res; 2008 Apr; 14(7):2075-81. PubMed ID: 18381947
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.
Mross K; Richly H; Frost A; Scharr D; Nokay B; Graeser R; Lee C; Hilbert J; Goeldner RG; Fietz O; Scheulen ME
Cancer Chemother Pharmacol; 2016 Aug; 78(2):405-17. PubMed ID: 27349901
[TBL] [Abstract][Full Text] [Related]
20. A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.
Raymond E; Alexandre J; Faivre S; Goldwasser F; Besse-Hammer T; Gianella-Borradori A; Jego V; Trandafir L; Rejeb N; Awada A
Invest New Drugs; 2014 Feb; 32(1):94-103. PubMed ID: 23539344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
